** Hikma rises 3 pct after BAML upgrades to "buy"from "neutral"
** Says it sees generous synergies from Roxane Laboratoriesacquisition; expects co to shut either its own or Roxane's USgenerics manufacturing plant
** Adds minimal colour on current pipeline but some largeopportunities expected - sees $725-775m revenues in FY17
** Top riser on FTSE 100
(RM: alasdair.pal.thomsonreuters.com@reuters.net)